Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 86, Issue 1, Pages 49-53Publisher
WILEY
DOI: 10.1038/clpt.2009.41
Keywords
-
Categories
Funding
- University of Glasgow, Imperial College
- Chief Scientist Office [CAF/06/07] Funding Source: researchfish
- Medical Research Council [G0400503B] Funding Source: researchfish
Ask authors/readers for more resources
Smokers with asthma show a reduced response to inhaled corticosteroids. We hypothesized that a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist would be superior for the clinical treatment of these asthma patients. Forty-six smokers with asthma were randomized to inhaled beclometasone dipropionate (200 mu g per day) or rosiglitazone (8 mg per day) for 4 weeks. Rosiglitazone produced improvements in lung function (forced expiratory volume in 1 s (FEV1) = 183 ml, P = 0.051; forced expiratory flow between 25 and 75% of the forced vital capacity (FEF25-75) = 0.24 l/s, P = 0.030) as compared with inhaled beclometasone dipropionate. Further trials using PPAR-gamma agonists in steroid-resistant airway disease are indicated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available